<DOC>
	<DOCNO>NCT01162863</DOCNO>
	<brief_summary>Irritable bowel syndrome ( IBS ) common disorder present abdominal pain discomfort association alter bowel habit . IBS subcategorized three type accord predominant bowel movement pattern : IBS constipation ( IBS-C ) , IBS diarrhea ( IBS-D ) , mixed-IBS ( IBS-M ) . The exact cause IBS remain incompletely understood , proposed mechanism include abnormal motility , visceral hypersensitivity , abnormal brain-gut interaction , psychological distress , alter GI tract motility . Lubiprostone , novel drug work activate colonic Chloride channel type 2 ( ClC-2 ) , approve use patient chronic idiopathic constipation recently approve treatment IBS-C woman age 18 older . By activate ClC-2 chloride channel colon , lubiprostone allow fluid secretion intestinal lumen lead soft stool consistency . In phase III clinical trial , patient IBS-C receive lubiprostone report improvement many symptom abdominal pain constipation . However , limited physiologic data explain exactly lubiprostone improve IBS-C symptom . The Smartpill novel non-digestible capsule capable measure intraluminal pH , pressure , temperature gastrointestinal ( GI ) tract . Smartpill show accurately measure whole gut well regional ( i.e . stomach , small bowel , colon ) transit time . The primary aim study determine effect lubiprostone whole GI tract transit , colonic transit , motility , intraluminal pH patient IBS-C evaluation Smartpill . The investigator propose study effect lubiprostone vs. placebo parameter , secondarily evaluate change parameter differ dos lubiprostone . The investigator hypothesize lubiprostone increase whole GI colonic transit compare placebo patient IBS . investigator expect change intraluminal pH lubiprostone compare placebo .</brief_summary>
	<brief_title>Effects Lubiprostone Gastrointestinal Transit &amp; pH Irritable Bowel Syndrome ( IBS ) With Constipation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Males female &gt; 18 year age Meet Rome III criterion IBS [ 2 ] : Recurrent abdominal pain discomfort least 3 day per month last 3 month associate 2 follow : 1 . Improvement defecation 2 . Onset associate change frequency 3 . Onset associate change form ( appearance ) stool *Criteria fulfil last 3 month symptom onset least 6 month prior diagnosis Fulfill Rome III stool consistency criterion IBSC [ 2 ] Hard lumpy stool &gt; 25 % bowel movement Loose ( mushy ) watery stool &lt; 25 % bowel movement Capable independently complete requirement study include return require visit Able provide write informed consent study participation Willing discontinue prohibit medication study participation Documentation normal colonoscopy within last 5 year age 50 year ( sigmoidoscopy less age 50 ) Documentation normal thyroid stimulate hormone ( TSH ) level , complet blood count ( CBC ) electrolyte panel within prior 3 year Females childbearing potential must negative urine serum pregnancy test screening Females childbearing potential must use effective mean contraception course study Hormonal ( oral , injectable , implantable , cervical/vaginal ring patch ) Doublebarrier ( condom and/or diaphragm spermicide ) intrauterine device provide care health care professional Abstinence , case documentation counsel record Unable understand provide write informed consent Pregnant nursing Patients IBSD , IBSM unsubtyped IBS Rome III criterion [ 2 ] IBS diarrhea ( IBSD ) 1 . Loose ( mushy ) watery stool &gt; 25 % bowel movement 2 . Hard lumpy stool &lt; 25 % bowel movement Mixed IBS ( IBSM ) 1 . Hard lumpy stool &gt; 25 % bowel movement 2 . Loose ( mushy ) watery stool &gt; 25 % bowel movement Unsubtyped IBS 1 . Insufficient abnormality stool pattern meet criterion IBSC , IBSD IBSM Documented allergy intolerance lubiprostone Failure balloon expulsion test Inability expel 50cc balloon within 1 minute Use drug know affect gastrointestinal motility 1 . Laxatives ( stable dos fiber take minimum 4 week allow ) Osmotic laxative : Magnesium hydroxide , Polyethylene glycol , Lactulose , Sorbitol Stimulant laxatives : Bisacodyl , Anthraquinones ( senna ) , Misoprostol 2 . Prokinetic agent : Metoclopramide , domperidone , erythromycin 3 . Antidiarrheal agent : Loperamide , Diphenoxylate , Bismuth 4 . Antispasmotics : Dicyclomine , Hyoscyamine 5 . Opioid , narcotic , opioid/narcoticcontaining analgesic : Morphine , Hydrocodone , Codeine , Methadone , Propoxyphene 6 . Probiotics 7 . Systemic antibiotic within last 3 month 8 . Recently initiate antidepressant ( stable dose &gt; 2 month nonGI condition allow ) 9 . Benzodiazepines * Subjects take prohibited medication require stop screening visit remain completion study . Initiation dietary change potentially alter bowel transit within 4 week Comorbid medical problem may affect gastrointestinal transit motility 1 . Previous surgery involve stomach , small bowel colon ( prior appendectomy , cholecystectomy , polypectomy allow ) 2 . Previous history small bowel obstruction reason 3 . History gastrointestinal malignancy 4 . History dyssynergic defecation 5 . Unexplained nausea vomit 6 . History inflammatory bowel disease ( Crohn 's ulcerative colitis ) 7 . History microscopic colitis ( lymphocytic collagenous colitis ) 8 . History Hirschsprung 's disease 9 . Severe complicate diverticular disease 10 . Chronic pancreatitis 11 . History celiac disease 12 . History eat disorder ( anorexia nervosa bulimia ) 13 . Cirrhosis 14 . Chronic hepatitis B C infection 15 . HIV infection 16 . Diabetes 17 . Systemic sclerosis ( scleroderma ) 18 . Amyloidosis 19 . Untreated thyroid disease 20 . Chronic pulmonary disease 21 . Severe renal insufficiency renal failure 22 . Current recent history ( within last 6 month ) : Diverticulitis , Duodenal gastric ulcer , Acute pancreatitis , Ileus Contraindications SmartPillÂ® ( addition ) : Cardiac pacemaker , defibrillator , implant electromagnetic device , Known Zenker 's diverticulum , Dysphagia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>IBSC</keyword>
	<keyword>irritable bowel syndrome</keyword>
	<keyword>constipation</keyword>
</DOC>